Kymera Therapeutics: Pay

Kymera Therapeutics paid its 5 named executives $23.6M in total in FY2025 (Dec).

Pay of each named executive

Brian Adams, J.D.Chief Legal Officer
FY2025 (Dec)
1 year
Noah Goodman, MBAChief Business Officer
FY2025 (Dec)
1 year
Jared Gollob, M.D.Chief Medical Officer
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)
FY2022 (Dec)Not disclosed
FY2021 (Dec)Not disclosed
5 years
Bruce Jacobs, CFA, MBAChief Financial Officer
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)
FY2022 (Dec)Not disclosed
FY2021 (Dec)Not disclosed
5 years

CEO pay against the pay peers

In FY2025 (Dec), the median CEO pay of the 9 peers with pay on file was $10.7M. The CEO of Kymera Therapeutics was paid $8.5M, 20% below the median.

  1. 1Scholar Rock Holding
  2. 2Viking Therapeutics
  3. 3Revolution Medicines
  4. 4Protagonist Therapeutics
  5. 5Immunovant
  6. 6IDEAYA Biosciences
  7. 7Kymera Therapeutics
  8. 8Vera Therapeutics
  9. 9Beam Therapeutics
  10. 10Denali Therapeutics
  11. 11ApogeeTherapeuticsNot disclosed
  12. 12ArcellxNot disclosed
  13. 13ArvinasNot disclosed
  14. 14Avidity BiosciencesNot disclosed
  15. 15BiohavenNot disclosed
  16. 16Dyne TherapeuticsNot disclosed
  17. 17ImmunityBioNot disclosed
  18. 18NuvalentNot disclosed
  19. 19VaxcyteNot disclosed

Pay of each named executive comes from the Summary Compensation Table of each proxy statement. Realized pay adds the value of options used and stock that vested. CEO pay of each peer comes from its own Pay versus Performance table.